COMMUNIQUÉS West-GlobeNewswire

Roche launches the cobas MPX-E assay, a new 4-in-1 donor screening test to further safeguard the global blood supply
30/03/2026
The cobas MPX-E test provides four critical results (for HIV, HCV, HBV, and HEV) in a single test, increasing laboratory efficiency and decreasing healthcare costs. The new test delivers faster turnaround times and [...]
Idorsia’s daridorexant delivers outstanding results in a Phase 2 study in children with insomnia disorder
30/03/2026
Ad hoc announcement pursuant to Art. 53 LR Phase 2 results show a statistically significant dose-dependent response on total sleep time with clinically meaningful improvements across multiple sleep measures in children [...]
Camila Japur joins Tecan as Chief Financial Officer
30/03/2026
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Camila Japur joins Tecan as Chief Financial Officer Männedorf, Switzerland, March 30, 2026 – The Tecan Group (SIX Swiss Exchange: [...]
NANOBIOTIX annonce la présentation des premières données de l’étude de phase 2 randomisée évaluant JNJ-1900 (NBTXR3) dans le cancer du poumon inopérable de stade III
30/03/2026
Données présentées par Johnson & Johnson lors de la conférence annuelle européenne 2026 sur le cancer du poumon (ELCC) PARIS et CAMBRIDGE, Mass., 30 mars 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO – NASDAQ [...]
NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
30/03/2026
Data presented by Johnson & Johnson at the 2026 European Lung Cancer Conference PARIS and CAMBRIDGE, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late- [...]
Draupnir Bio announces transformational publication detailing extracellular targeted protein degradation technology in Cell Chemical Biology
30/03/2026
Draupnir’s novel SORTAC platform expands reach of targeted protein degradation to extracellular proteins, demonstrating in vitro and in vivo efficacy against difficult-to-drug targets Study further details platform [...]
Medical AI Named First-Ever Recipient of ACC Global Digital Health Award at American College of Cardiology Annual Scientific Session
29/03/2026
AI platform recognized for real-world clinical impact through analysis of raw 12-lead ECG data, enabling earlier detection of multiple cardiovascular diseases NEW ORLEANS, March 29, 2026 (GLOBE NEWSWIRE) -- Medical AI, [...]
Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%
29/03/2026
Fabhalta lowered likelihood of progression to kidney failure by 43% in APPLAUSE-IgAN study 1 40.7% of patients on Fabhalta demonstrated sustained reduction of protein in urine over two years 1 Fabhalta granted priority [...]
Gelatin Trick 2026 Warning: Does the Viral Gelatin Trick Recipe Actually Work? — Pink Gelatin Trick, Ice Gelatin Trick, Bariatric Jello, and Why Consumers Are Choosing Gelatine Sculpt Instead (New Investigation)
28/03/2026
As interest in the gelatin trick surges in 2026, consumers across social platforms and search engines are asking whether the viral recipe actually works — this release addresses commonly circulating questions about the [...]
Gelatide Drops Under Investigation: Full Gelatide-1 Consumer Report Reveals Shocking Hidden Risks & Fake Gelatin Trick Recipe
28/03/2026
A 2026 informational consumer evaluation of Gelatide marketing claims, ingredient research context, Akkermansia muciniphila and proprietary blend dosage transparency, the viral gelatin trick weight loss trend, pricing [...]
New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
28/03/2026
The results of the Phase 3 VALOR trial were published in the New England Journal of Medicine , underscoring the practice-changing potential of brepocitinib 30 mg once-daily in dermatomyositis Brepocitinib 30 mg was [...]
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
28/03/2026
Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated with sonelokimab ( [...]
Steel Power Male Enhancement Claims Evaluated: Complete SteelPower Performance Report for Men
28/03/2026
A 2026 report outlining Steel Power ingredient research, male enhancement supplement positioning, performance claim context, pricing structure, and what the SteelPower formula label discloses for men Aurora, CO, March [...]
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
28/03/2026
In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving clear / almost clear [...]
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting
28/03/2026
Featured presentation highlights positive BroADen Phase 1b atopic dermatitis trial results supporting KT-621’s compelling oral profile Parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, [...]
SonusZen Claims Evaluated: Testing the Legitimacy of Sonus Zen Formulation for Hearing Support
28/03/2026
A 2026 informational overview of the SonusZen hearing support formulation, Sonus Zen ingredient transparency and B vitamin research context, tinnitus supplement category positioning, auditory health claims, and what [...]
Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting
28/03/2026
Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the INTEGUMENT program ZORYVE cream improved signs and symptoms of mild to moderate [...]
Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis
28/03/2026
Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%) Quality‑of‑life improvements and itch relief emerged [...]
Communiqué de presse : AAD : Sanofi présente de nouveaux résultats de phase 3 pour l'amlitelimab dans la dermatite atopique lors d'une session de dernière minute
28/03/2026
AAD : Sanofi présente de nouveaux résultats de phase 3 pour l'amlitelimab dans la dermatite atopique lors d'une session de dernière minute Dans les études de phase 3 COAST 1, COAST 2 et SHORE, l’amlitelimab, administré [...]

Pages